8-K: Tonix Pharmaceuticals Submits New Drug Application to FDA for Fibromyalgia Treatment TNX-102 SL

Tonix Pharmaceuticals has submitted a New Drug Application to the FDA for TNX-102 SL, a potential new treatment for fibromyalgia, based on positive results from two Phase 3 clinical trials.

Summary

• Tonix Pharmaceuticals has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TNX-102 SL (sublingual cyclobenzaprine HCl) 5.6 mg for the treatment of fibromyalgia.
• The NDA submission is supported by data from two successful Phase 3 clinical trials, RELIEF and RESILIENT, which demonstrated statistically significant reductions in daily pain compared to placebo.
• TNX-102 SL is a non-opioid, centrally acting analgesic that has been granted Fast Track designation by the FDA.
• Fibromyalgia affects over 10 million adults in the U.S., and if approved, TNX-102 SL would be the first new drug for treating fibromyalgia in more than 15 years and the first of a new class of medicines for the condition.
• The company believes TNX-102 SL works by targeting the non-restorative sleep that is characteristic of fibromyalgia.
• The most common adverse event in the trials was tongue or mouth numbness, which was mild and rarely led to study discontinuation.

Sentiment

Score: 8

Explanation: The document is positive due to the successful NDA submission and the potential for a new treatment option for fibromyalgia. The company has achieved a significant milestone, and the drug has shown promising results in clinical trials. However, there are still risks associated with regulatory approval and commercialization.

Positives

• The NDA submission is supported by two successful Phase 3 clinical trials.
• TNX-102 SL has received Fast Track designation from the FDA, potentially expediting the review process.
• The drug is a non-opioid alternative for pain management.
• The drug targets a key symptom of fibromyalgia, non-restorative sleep.
• The adverse event profile was generally well tolerated with no new safety signals observed.
• The company has patents protecting the drug's formulation until 2034.

Negatives

• The most common adverse event was tongue or mouth numbness, although it was mild and temporary.
• The FDA has a 60-day filing review period to determine if the NDA is complete and accepted for review, which introduces uncertainty.
• There is no guarantee of FDA approval, and the company faces risks related to regulatory hurdles.

Risks

• There is a risk that the FDA may not approve the NDA.
• The company faces risks related to the timing and progress of clinical development.
• There are risks related to the failure to successfully market the product if approved.
• The company may need additional financing.
• There are uncertainties of patent protection and litigation.
• There are uncertainties of government or third party payor reimbursement.
• The company faces substantial competition in the pharmaceutical market.

Future Outlook

The company expects a 2025 date for an FDA decision on approval, based on the Prescription Drug User Fee Act (PDUFA), if the NDA is accepted for review.

Management Comments

• Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, stated that the NDA submission is a critical milestone in potentially bringing a new first-line treatment option to the large and dissatisfied fibromyalgia population.
• Gregory Sullivan, M.D., Chief Medical Officer of Tonix Pharmaceuticals, commented that there remains a need for new treatment options for fibromyalgia patients despite three existing FDA-approved medications.

Industry Context

The submission of the NDA for TNX-102 SL addresses a significant unmet need in the fibromyalgia treatment landscape, where existing therapies have limitations and patient dissatisfaction is common. The drug's novel mechanism of action and potential to be the first of a new class of medicines could position it as a significant player in the market.

Comparison to Industry Standards

• The existing FDA-approved drugs for fibromyalgia include Pfizer's Lyrica (pregabalin), approved in 2008, and Lilly's Cymbalta (duloxetine) and AbbVie's Savella (milnacipran), approved in 2007 and 2009, respectively.
• TNX-102 SL is positioned as a potential first-in-class tricyclic medicine for fibromyalgia, offering a different mechanism of action compared to the existing gabapentinoid and SNRI classes.
• The Phase 3 trials for TNX-102 SL demonstrated statistically significant results on the primary endpoint of reducing widespread pain, which is a key benchmark for fibromyalgia treatments.
• The drug's sublingual administration and focus on targeting non-restorative sleep differentiate it from existing oral medications.

Stakeholder Impact

• Shareholders may see a positive impact on the stock price due to the NDA submission.
• Patients with fibromyalgia may benefit from a new treatment option.
• Employees of Tonix Pharmaceuticals may see increased job security and growth opportunities.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• The FDA will conduct a 60-day filing review to determine if the NDA is complete and accepted for review.
• If accepted, the company expects a 2025 date for an FDA decision on approval.

Key Dates

Keywords

Fibromyalgia, TNX-102 SL, New Drug Application, FDA, Analgesic, Clinical Trials, Pain Management, Non-opioid, Fast Track Designation, Cyclobenzaprine